Actionable news
All posts from Actionable news
Actionable news in ENDP: Endo Health Solutions Inc.,

Endo Provides Update on Use of Specialty Pharmacies

  • Endo utilizes specialty pharmacy services primarily for certain physician-administered branded products in the U.S., including: XIAFLEX®, AVEED®, TESTOPEL®, Supprelin® LA, Vantas® and Valstar®.
  • The percentage of the company's projected U.S. Branded 2015 revenues (midpoint of 2015 guidance) that flow through specialty pharmacies is less than 10 percent, which represents approximately 3 percent of the company's projected overall 2015 revenues (midpoint of 2015 guidance).
  • The specialty pharmacies used by Endo are fully independent of the company. Endo does not have any ownership interest in, consolidate financial results of or have affiliations with any specialty pharmacy.

About Endo International plc
Endo International plc (NASDAQ: ENDP) (TSX: ENL) is a global specialty pharmaceutical company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications though its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at

Safe Harbor Statement

This press release contains forward-looking statements, including but not limited to statements relating to revenue forecasts and other statements that refer to Endo's expected, estimated...